PMID- 27124204 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20180213 IS - 1744-8336 (Electronic) IS - 1478-7210 (Linking) VI - 14 IP - 6 DP - 2016 Jun TI - HACEK endocarditis: a review. PG - 539-45 LID - 10.1080/14787210.2016.1184085 [doi] AB - INTRODUCTION: The HACEK group, referring to Haemophilus spp., Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae, is a rare cause of infective endocarditis (IE). It causes the majority of Gram-negative endocarditis cases and has an excellent prognosis and simple management if properly identified. However, delay in diagnosis and associated complications can render the infection fatal. AREAS COVERED: Over the past few decades, there have been tremendous advancements in understanding the manifestations and progression of HACEK endocarditis (HE). This review tackles the epidemiology of HE, the microbiological characteristics of each organism in the HACEK group, the methods used to diagnose HE, the clinical manifestations, complications, and mortality of patients with HE, as well as the recommended treatment and preventive methods. Expert Commentary: The lack of robust randomized controlled trials in diagnosis and treatment of HE makes it difficult to determine the optimal management of such infections. Nevertheless, advancements in culturing methods have shown progress in isolating and identifying these fastidious organisms. Positive blood cultures for any of the HACEK organisms in the setting of no definite focus of infection is highly suggestive of HE. In such cases, treatment with ceftriaxone or a fluoroquinolone, even without obtaining antibiotic susceptibilities, should be initiated. Moreover, the decision to proceed with surgical intervention should be individualized. As is the case for other IE, HE requires the collaboration of a multidisciplinary team consisting of the infectious disease specialist, cardiologist, cardiothoracic surgeon, and the microbiologist. FAU - Sharara, Sima L AU - Sharara SL AD - a School of Medicine, American University of Beirut , Beirut , Lebanon. FAU - Tayyar, Ralph AU - Tayyar R AD - b Division of Infectious Diseases, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon. FAU - Kanafani, Zeina A AU - Kanafani ZA AD - b Division of Infectious Diseases, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon. FAU - Kanj, Souha S AU - Kanj SS AD - b Division of Infectious Diseases, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon. LA - eng PT - Journal Article PT - Review DEP - 20160517 PL - England TA - Expert Rev Anti Infect Ther JT - Expert review of anti-infective therapy JID - 101181284 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Aggregatibacter/drug effects/isolation & purification MH - Anti-Bacterial Agents/administration & dosage/therapeutic use MH - Cardiobacterium/drug effects/isolation & purification MH - Echocardiography MH - Eikenella corrodens/drug effects/isolation & purification MH - Endocarditis, Bacterial/diagnosis/drug therapy/epidemiology/*microbiology MH - Gram-Negative Bacteria/*drug effects/isolation & purification MH - Haemophilus/drug effects/isolation & purification MH - Humans MH - Kingella/drug effects/isolation & purification MH - Microbial Sensitivity Tests OTO - NOTNLM OT - Aggregatibacter actinomycetemcomitans OT - Cardiobacterium hominis OT - Eikenella corrodens OT - HACEK endocarditis OT - Haemophilus spp OT - Kingella kingae OT - infective endocarditis EDAT- 2016/04/29 06:00 MHDA- 2017/10/17 06:00 CRDT- 2016/04/29 06:00 PHST- 2016/04/29 06:00 [entrez] PHST- 2016/04/29 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] AID - 10.1080/14787210.2016.1184085 [doi] PST - ppublish SO - Expert Rev Anti Infect Ther. 2016 Jun;14(6):539-45. doi: 10.1080/14787210.2016.1184085. Epub 2016 May 17.